Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

A cost analysis of implementing a behavioral weight loss intervention in community mental health settings: Results from the ACHIEVE trial.

Janssen EM, Jerome GJ, Dalcin AT, Gennusa JV 3rd, Goldsholl S, Frick KD, Wang NY, Appel LJ, Daumit GL.

Obesity (Silver Spring). 2017 Jun;25(6):1006-1013. doi: 10.1002/oby.21836. Epub 2017 Apr 11.

PMID:
28398006
2.

Alterations of Lipid-Lipoprotein and Leptin in Bipolar Disorder Associated with Clinic Process.

Bülbül F, Eryiğit AG, Erbağci AB, Selek S, Savaş H.

Noro Psikiyatr Ars. 2014 Mar;51(1):52-56. doi: 10.4274/npa.y6668. Epub 2014 Mar 1.

3.

Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.

Bond DJ, Silveira LE, MacMillan EL, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN.

Transl Psychiatry. 2017 Mar 28;7(3):e1071. doi: 10.1038/tp.2017.42.

4.

Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges.

Kim Y, Santos R, Gage FH, Marchetto MC.

Front Cell Neurosci. 2017 Feb 14;11:30. doi: 10.3389/fncel.2017.00030. eCollection 2017. Review.

5.

Metabolic syndrome and central obesity in depression: A cross-sectional study.

Agarwal A, Agarwal M, Garg K, Dalal PK, Trivedi JK, Srivastava JS.

Indian J Psychiatry. 2016 Jul-Sep;58(3):281-286. doi: 10.4103/0019-5545.192021.

6.

Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial.

Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N.

Psychopharmacol Bull. 2011 May 15;44(2):73-84.

7.

The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research.

Fountoulakis KN, Vieta E, Young A, Yatham L, Grunze H, Blier P, Moeller HJ, Kasper S.

Int J Neuropsychopharmacol. 2016 Oct 11. pii: pyw072. doi: 10.1093/ijnp/pyw072. [Epub ahead of print] Review.

8.

The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.

Chang TT, Chen SL, Chang YH, Chen PS, Chu CH, Chen SH, Huang SY, Tzeng NS, Wang LJ, Wang TY, Li CL, Chung YL, Hsieh TH, Lee IH, Chen KC, Yang YK, Hong JS, Lu RB, Lee SY.

Medicine (Baltimore). 2016 Jun;95(24):e3488. doi: 10.1097/MD.0000000000003488.

9.

Perceptions of strategies for successful weight loss in persons with serious mental illness participating in a behavioral weight loss intervention: A qualitative study.

Vazin R, McGinty EE, Dickerson F, Dalcin A, Goldsholl S, Oefinger Enriquez M, Jerome GJ, Gennusa JV, Daumit GL.

Psychiatr Rehabil J. 2016 Jun;39(2):137-46. doi: 10.1037/prj0000182. Epub 2016 Apr 7.

10.

Long-term risk of myocardial infarction and stroke in bipolar I disorder: A population-based Cohort Study.

Prieto ML, Schenck LA, Kruse JL, Klaas JP, Chamberlain AM, Bobo WV, Bellivier F, Leboyer M, Roger VL, Brown RD Jr, Rocca WA, Frye MA.

J Affect Disord. 2016 Apr;194:120-7. doi: 10.1016/j.jad.2016.01.015. Epub 2016 Jan 13.

11.

Associations Between Gender and Obesity Among Adults with Mental Illnesses in a Community Health Screening Study.

Jonikas JA, Cook JA, Razzano LA, Steigman PJ, Hamilton MM, Swarbrick MA, Santos A.

Community Ment Health J. 2016 May;52(4):406-15. doi: 10.1007/s10597-015-9965-2. Epub 2015 Dec 28.

12.

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC.

Acta Psychiatr Scand. 2015 Jun 26. doi: 10.1111/acps.12460. [Epub ahead of print]

13.

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL.

Gen Hosp Psychiatry. 2015 May-Jun;37(3):199-222. doi: 10.1016/j.genhosppsych.2015.03.004. Epub 2015 Mar 14. Review.

15.

Co-morbidity in Bipolar Disorder: A Retrospective Study.

Munoli RN, Praharaj SK, Sharma PS.

Indian J Psychol Med. 2014 Jul;36(3):270-5. doi: 10.4103/0253-7176.135377.

16.

Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis.

Prieto ML, Cuéllar-Barboza AB, Bobo WV, Roger VL, Bellivier F, Leboyer M, West CP, Frye MA.

Acta Psychiatr Scand. 2014 Nov;130(5):342-53. doi: 10.1111/acps.12293. Epub 2014 May 22. Review.

17.

Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia.

Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Patterson TL, Harvey PD.

Bipolar Disord. 2014 Jun;16(4):422-31. doi: 10.1111/bdi.12200. Epub 2014 Apr 12.

18.

Assessment of insulin resistance and metabolic syndrome in drug naive patients of bipolar disorder.

Guha P, Bhowmick K, Mazumder P, Ghosal M, Chakraborty I, Burman P.

Indian J Clin Biochem. 2014 Jan;29(1):51-6. doi: 10.1007/s12291-012-0292-x. Epub 2013 Jan 10.

19.

Phentermine, sibutramine and affective disorders.

An H, Sohn H, Chung S.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):7-12. doi: 10.9758/cpn.2013.11.1.7. Epub 2013 Apr 24.

20.

Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden.

Westman J, Hällgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U.

BMJ Open. 2013 Apr 18;3(4). pii: e002373. doi: 10.1136/bmjopen-2012-002373. Print 2013.

Supplemental Content

Support Center